The impact of direct‐acting antivirals on hepatitis C viraemia among people who inject drugs in England; real‐world data 2011–2018
| Autor: | Sema Mandal, Emily-Rose Phipps, Sara Croxford, Nasra Hassan, Claire Edmundson, Sharon J. Hutchinson, Justin Shute, Vivian Hope, Ross J Harris, Ellen Heinsbroek, Samreen Ijaz, Matthew Hickman, Megan Bardsley, Katherine Sinka |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Elimination Direct-acting antivirals Logistic regression DIRECT ACTING ANTIVIRALS Antiviral Agents Virology Prevalence Humans Medicine Viremia Substance Abuse Intravenous Male gender Harm reduction Hepatology Hepatitis C virus business.industry Treatment as prevention Odds ratio Hepatitis C Hepatitis C Chronic medicine.disease Infectious Diseases Pharmaceutical Preparations business People who inject drugs Real world data Demography |
| Zdroj: | et al. 2021, ' The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011–2018 ', Journal of Viral Hepatitis, vol. 28, no. 10, pp. 1452-1463 . https://doi.org/10.1111/jvh.13575 |
| ISSN: | 1365-2893 1352-0504 |
| Popis: | Background: Direct-acting antiviral (DAA) therapy for anybody with viraemic HCV infection has been scaled-up in England since 2017. To assess early impacts, we described trends in, and factors associated with, HCV viraemia among people who inject drugs (PWID). We also examined trends in self-reported treatment access.Methods: Bio-behavioural data from an annual, national surveillance survey of PWID (2011 to 2018) estimated trends in viraemic prevalence among HCV antibody-positive PWID. Multivariable logistic regression identified characteristics independently associated with viraemia. Trends in treatment access were examined for PWID with known infection.Findings: Between 2011 and 2016, viraemic prevalence among antibody-positive PWID remained stable (2011, 57.7%; 2016, 55.8%) but decreased in 2017 (49.4%) and 2018 (50.4%) (both p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|